NYSE:ATS ATS Q2 2026 Earnings Results & Report $17.83 +0.31 (+1.77%) Closing price 11/18/2026 03:59 PM EasternExtended Trading$17.80 -0.02 (-0.14%) As of 11/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ATS beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released November 5, 2025. The company reported EPS of $0.33 versus the $0.31 consensus estimate, while revenue of $524.03 million fell short of the $721.51 million estimate by $197.48 million. Revenue increased 18.9% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateNovember 5, 2025TimeBefore Market OpensConference Call8:30 AM ET ATS EPS ResultsActual EPS$0.33Consensus EPS $0.31Beat/MissBeat by +$0.02One Year Ago EPS$0.25EPS Beat Rate4 of last 8 quartersATS Revenue ResultsActual Revenue$524.03 millionExpected Revenue$721.51 millionBeat/MissMissed by -$197.48 millionYoY Revenue Growth+18.90%Upcoming EarningsATS' Q3 2027 earnings is estimated for Wednesday, February 3, 2027, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress ReleaseEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by ATS Q2 2026 Earnings Call TranscriptProvided by QuartrNovember 5, 2025ShareShareShare This ReportLink copied to clipboard.Key Takeaways Positive Sentiment: Q2 revenues were $729 million (up ~19% YoY) with adjusted operating earnings of $79.1 million (up 40% YoY), a 29.9% gross margin, and adjusted EPS of $0.45, driven by organic growth and services. Positive Sentiment: Order backlog of approximately $2.1 billion (life sciences ~$1.1 billion) and a trailing 12‑month book‑to‑bill of 1.12 indicate strong revenue visibility, with healthy funnels in radiopharma, auto‑injectors, food & beverage and a record energy backlog of $277 million. Negative Sentiment: Management expects approximately $15 million of restructuring charges in H2 to realign costs (payback <1 year), while non‑cash working capital remains elevated at 18.3% of revenues and net debt/adjusted EBITDA is 3.4x. Neutral Sentiment: Company reaffirmed full‑year high single‑digit revenue growth and margin improvement targets, issued Q3 revenue guidance of $700–$740 million, plans FY CapEx/intangible spend of $80–$100 million, and continues innovation and a prudent M&A pipeline (e.g., Comacare center, Illuminate platform). AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallATS Q2 202600:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipantsPresentationSkip to Participants Operator00:00:00Welcome to the ATS Corporation second quarter conference call and webcast. This call is being recorded on November 5th, 2025, at 8:30 A.M. Eastern Time. Following the presentation, we will conduct a question-and-answer session. I'd now like to turn the call over to David Ocampo, Head of Investor Relations at ATS. David OcampoHead of IR at ATS Corporation00:00:22Thank you, Operator, and good morning, everyone. On the call today are Ryan McLeod, Interim Chief Executive Officer of ATS, and Anne Cybulski, Interim Chief Financial Officer. Please note that our remarks today are accompanied by a slide deck, which can be viewed via our webcast and available at atsautomation.com. We caution that the statements made on the webcast and conference call may contain forward-looking information and are a cautionary statement regarding such information, including the material factors that could cause actual results to differ materially from the statements, and the material factors or assumptions applied in making the statements are detailed in slide three of the slide deck. Now it's my pleasure to turn the call over to Ryan. Ryan McLeodInterim CEO at ATS Corporation00:01:05Thank you, David, and welcome to ATS. It's great to have you on the team. Good morning, everyone, and thank you for joining us today. Today, ATS reported second quarter results for fiscal 2026, highlighted by strong organic revenue growth and an improvement in adjusted earnings margins in line with our expectations. These results reflect the strength of our decentralized organization and the collective efforts of our teams. During this leadership transition period, it is business as usual as we build on our culture of continuous improvement through the ATS Business Model, with a clear focus on creating value across our diversified global portfolio. As we've previously discussed, the board began its search for a permanent CEO over the summer and is now well into the process. While our entire senior leadership team remains intensely focused on advancing our strategic growth priorities. Ryan McLeodInterim CEO at ATS Corporation00:02:00This morning, I will update you on the business and our markets, and Anne will provide her financial report. Starting with our financial value drivers, order bookings were CAD 734 million, up 6% sequentially, reflecting solid performance and strength across our diversified end markets. Q2 revenues were CAD 729 million, up 19% from Q2 last year, driven primarily by organic growth and supported by solid performance and services. Adjusted earnings from operations in Q2 were CAD 79 million. Moving to our outlook, order backlog of approximately CAD 2.1 billion continues to provide good revenue visibility. Our opportunity funnel remains healthy and well-diversified. Within life sciences, order backlog at quarter end remains strong at CAD 1.1 billion. Supported by demand across sub-markets. Importantly, the wider life sciences funnel includes a mix of opportunities in radiopharma, auto injectors, diagnostic wearables, and automated pharmacies. Ryan McLeodInterim CEO at ATS Corporation00:03:10ATS works with a broad set of leading GLP-1 customers, providing diversification across platforms and drug delivery formats. In addition, as other applications for GLP-1 therapies emerge, including for treatment of cardiovascular and neurological disorders, ATS is well-positioned to support providers of drug delivery solutions. Momentum remains especially strong in the radiopharma space, supported by investments in production capacity and the advancement of new therapeutics. To support growth and meet evolving customer needs, our recently opened Comecer Competence Center in Indianapolis delivers enhanced service capabilities and faster response times for customers in North America. During the quarter, Comecer secured new wins in diagnostic and therapeutic projects, advancing next-generation capabilities for radiopharmaceutical production. Within the lab research space, government-funded customers continue to take a more measured approach to capital investment, given the changing U.S. funding environment. Ryan McLeodInterim CEO at ATS Corporation00:04:16While orders from these customers represent a small portion of our overall business, our lab equipment businesses have been leveraging the common ABM framework to improve joint commercial initiatives and to expand shared access to their individual customer bases. In food and beverage, quarter-end backlog was CAD 218 million, with customer wins in multiple regions during Q2 in primary processing and in sorting and inspection, supported by internally developed products and technology. Our food and beverage funnel remains strong, with customer investment focused on automation that enhances yield, quality, and energy efficiency across our comprehensive solutions, spanning primary processing, inspection, primary and secondary packaging, and aftermarket support. In energy, order backlog was a record CAD 277 million, up 154% over Q2 last year. This increase was driven primarily by nuclear refurbishment projects as operators continued to invest in life extension programs. Ryan McLeodInterim CEO at ATS Corporation00:05:25The nuclear funnel continues to broaden beyond refurbishment, covering service and new nuclear reactor builds, including small modular reactors. On new builds, initial activity centers on early-phase design and engineering programs that support modular fabrication of reactor structures and fuel handling systems. These programs position ATS to participate as projects move into commercial deployment. While order timing may vary, supportive policies and growing demand for clean and reliable energy, including from data centers, support a strong outlook for nuclear. In consumer products, our funnel remains stable, with ongoing programs in personal care and household goods packaging, along with warehouse automation. In transportation, the funnel consists of relatively smaller opportunities consistent with our expectations. Our capabilities in battery assembly allow us to win and deliver on these opportunities as they arise. Ryan McLeodInterim CEO at ATS Corporation00:06:28Overall, our balanced exposure to regulated and growth-oriented end markets, along with a strong order backlog, positions us well to navigate the current environment. Turning to the ATS business model, it remains central to how we operate and is well embedded into our culture. I recently attended our Global ABM Conference, where our continuous improvement leaders from across the business demonstrated their commitment to driving the ABM, along with a renewed focus on creating impact for customers and shareholders through disciplined execution and operational efficiency. I continue to be impressed by our team's use of the ABM to drive value within their operations. This includes daily visual management tools to create immediate focus and drive problem-solving, as well as sustained process improvements through Kaizen and strategy deployment. On M&A, our funnel is healthy and active as we cultivate and review opportunities that align with our long-term strategic priorities. Ryan McLeodInterim CEO at ATS Corporation00:07:31We continue to integrate our more recent acquisitions and drive further synergies, particularly through shared customer access and integrated offerings from across our portfolio. We're also working diligently to return leverage to within our target range, with good progress made during the quarter. On innovation, we have further developed our Illuminate Manufacturing Intelligence platform to support new deployments at select businesses, including some of our more recent acquisitions. These efforts allow us to efficiently integrate equipment, standardize data capture and analytics, and improve visibility across our installed base. The 2025 ATS Innovation Summit is being held this week, bringing together key innovation leaders from across the ATS organization. Through panels and workshops, the summit seeks to foster a unified innovation ecosystem, accelerate product development, and strengthen collaboration on translating emerging technologies into customer value. Ryan McLeodInterim CEO at ATS Corporation00:08:31Our investment in innovation has been core to our strategy and remains a key differentiator for ATS. In summary, our results this quarter reflect good progress across our value drivers, supported by a strong backlog. Our advantages today, including our global footprint, our talented workforce aligned around our ABM culture, and our strong customer relationships, will serve us well to advancing our growth and long-term value creation strategy for the future. Now, I will turn the call over to Anne. Anne, over to you. Anne CybulskiInterim CFO at ATS Corporation00:09:05Thank you, Ryan, and good morning, everyone. Starting with our operating results for the quarter, order bookings were CAD 734 million, down 1.1% compared to Q2 last year, which included several larger enterprise bookings in life sciences. This was largely offset by growth in all other markets over last year. Our trailing 12-month book-to-bill ratio at the end of Q2 remained healthy at 1.12x to 1x and was at or above 1x across all market verticals. Revenues for the second quarter were CAD 729 million, up 18.9% compared to last year, including organic growth of 12.6%, along with a 3.9% benefit from foreign exchange translation and a 2.4% contribution from acquisitions. Moving to earnings, second quarter adjusted earnings from operations were CAD 79.1 million, a 40% increase from prior year, primarily on higher revenue volumes. Gross margin for Q2 was 29.9%, a 36 basis point increase on Q2 last year. Anne CybulskiInterim CFO at ATS Corporation00:10:15On SG&A, excluding acquisition-related amortization and transaction costs, expenses in the first quarter totaled CAD 134.5 million. A CAD 14.5 million increase over the prior year, primarily a result of incremental SG&A from acquired companies and FX translation impact. Excluding a recovery related to forfeitures from our former CEO's departure and mark-to-market impact related to changes in our share price, stock-based compensation expense was CAD 4.3 million in Q2. Earnings per share were CAD 0.45 on an adjusted basis. Moving to our outlook, we ended the quarter with an order backlog of approximately CAD 2.1 billion. Q3 revenues are expected to be in the range of CAD 700 million-CAD 740 million. As a reminder, this assessment is updated every quarter, taking into account revenue expectations from current order backlog and new orders booked and billed within the quarter. Anne CybulskiInterim CFO at ATS Corporation00:11:19This quarter, we have identified an opportunity to realign our cost structure to strategic focus areas and to drive global operational efficiencies. We estimate restructuring costs of approximately CAD 15 million will be incurred in the final half of this fiscal year, with an expected payback of less than one year. For clarity, there is no change to our expectations for full-year high single-digit revenue growth as previously disclosed. We continue to expect adjusted operating margin improvement on a full-year basis in fiscal 2026. ABM discipline and tools help to create focus across all of our value drivers, including margin expansion. The macro environment remains dynamic, including geopolitical tensions and trade and tariff considerations. As a reminder, the majority of our exports from Canada into the U.S. remain covered under the USMCA. Anne CybulskiInterim CFO at ATS Corporation00:12:15Our global and decentralized operating model positions us well to navigate market dynamics to serve customers where they are deploying capital. In this environment, ATS continues to execute well, maintaining leadership in our key sub-markets and driving progress on our growth priorities. Moving to the balance sheet. In Q2, cash flows from operating activities were CAD 28 million. Our non-cash working capital as a percentage of revenues was 18.3%. While timing of milestone billings and collections do impact this percentage, our focus on driving working capital efficiency across the business and our target of 15% remains unchanged. We expect to see improvement by the end of the fiscal year. During the quarter, we invested CAD 18.3 million in CapEx and intangible assets, reflecting our disciplined focus on innovation and strengthening our capabilities. Anne CybulskiInterim CFO at ATS Corporation00:13:14For fiscal 2026, we expect our CapEx and intangible investment to be within our previously disclosed range of CAD 80 million-CAD 100 million. On leverage, our net debt-to-adjusted EBITDA ratio was 3.4x. This progress since the beginning of the year supports our expectation of reducing leverage to within our target range of 2x-3x. In summary, we're pleased with second quarter results and with the alignment of our leadership team and global employee base as we continue to execute on our plans and drive the business forward. Our strong order backlog supports our outlook for sustained growth, and our expectations for revenue and margin expansion in fiscal 2026 are unchanged. ATS is leveraging our culture of continuous improvement and our embedded structural advantages to drive tangible value through a consistent, disciplined approach. Anne CybulskiInterim CFO at ATS Corporation00:14:11We are confident that our team's continued efforts will deliver value to both our customers and shareholders. Now, we will open the call to questions from our analysts. Operator, could you please provide instructions? Thank you. Operator00:14:25Thank you. We will now begin the question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. If you would like to withdraw your question, simply press star one again. We ask that you please limit yourself to two questions only. You may re-queue for any further questions. Your first question today comes from the line of Cherilyn Radbourne from TD Cowen. Your line is open. Cherilyn RadbourneManaging Director of Equity Research at TD Cowen00:14:49Thanks very much and good morning. When we look at your results, the one thing that is of some concern to us is that it appears bookings momentum has slowed over the last six months relative to the second half of last year. Just curious, what gives you confidence that that's just normal lumpiness in the business and not something more? Ryan McLeodInterim CEO at ATS Corporation00:15:13Hi, good morning, Cherilyn. So, I mean, a couple of things. First of all, I mean, when we look at the state of the business. There is normal course variability, and there are some larger programs which can really drive that. Our book-to-bill is healthy at 1.12x. From a backlog perspective, we're up about 14%, 13.5%, 14% year-over-year. We are in a really good position from a backlog standpoint. I think, importantly to your question. Funnel activity, and I talked about it a little bit in my prepared remarks, but in general, is healthy across our vertical markets. Life sciences, really good activity. Auto injectors remain very active. We're seeing a lot of activity in radiopharma as well as medical, general medical device wearables, contact lenses, automated pharmacy. A lot of activity across life sciences, which supports that outlook. Food continues to be strong. Ryan McLeodInterim CEO at ATS Corporation00:16:22We're seeing some really good uptake and interest based on what we're doing in primary processing, packaging, as well as some of the inspection and sorting capability that we have. Consumer stable, it's been very resilient. In transportation, as we expected, it's lower relative to where it was a couple of years ago, but there's still opportunities that are arising. I think the other area that we're seeing a lot of growth opportunity in is energy, and there's a lot happening. Refurbishment has continued to be active. We're seeing good activity in decommissioning and maybe a bit more mid to long term, but certainly accelerating, is the new nuclear space. Ryan McLeodInterim CEO at ATS Corporation00:17:11New builds, whether it's conventional technology or SMRs, we're seeing a lot of activity in that space and participating in a lot of early-stage projects to support the ongoing build-out that's going to be coming in the nuclear space. Overall, I mean, as I said, our funnels were very positive in terms of where they sit and support the continued growth that we expect. Cherilyn RadbourneManaging Director of Equity Research at TD Cowen00:17:40Okay, that's helpful, color. Just specifically, how did the services business perform in the second quarter? Along with that, are you intending to recruit someone to replace Simon Roberts to head that segment? Anne CybulskiInterim CFO at ATS Corporation00:17:58Hi, Cherilyn. I'll start with the numbers question. Overall, we're happy with the performance of the service business in the quarter, also on a year-to-date basis. I would call the performance strong. There were some EV numbers in the comparatives, but really good performance across other areas of the business. Services, as you know, are kind of recurring in nature. We have some in the numbers that are like upgrades that are less regular, but services remain strategic to our overall growth plans. Good performance, happy with what we're seeing across the business. I'll let Ryan comment on the other piece. Ryan McLeodInterim CEO at ATS Corporation00:18:43Yeah. Cherilyn, the short answer is yes. I mean, first of all, we're very pleased that Simon has taken on the leadership role within our packaging and food tech business. Simon's a longtime ATS executive, very experienced, knows the business very well. After sales is an attractive opportunity within packaging and food tech. Very well aligned with some of Simon's background. We will be replacing that role, yes. Cherilyn RadbourneManaging Director of Equity Research at TD Cowen00:19:19That's my two. Thank you. Ryan McLeodInterim CEO at ATS Corporation00:19:21Thank you. Operator00:19:23Your next question comes from a line of Sabahat Khan from RBC. Your line is open. Sabahat KhanManaging Director of Global Research at RBC00:19:29Great. Thanks for the good morning. I guess just looking ahead to sort of the back half of this year and to fiscal 2027, as you think about the margin trajectory. Do you think at this point in the cycle, do you think it's more driven by some incremental initiatives you need to take on the cost reduction side? I know you're now restructuring a little bit this morning. Or is it more from sales picking up on a more consistent basis over the next four to six quarters that sort of gets you moving towards the medium to longer-term targets you have on the margin side? Thanks. Anne CybulskiInterim CFO at ATS Corporation00:19:58Hi, good morning, Saba. Let me start with just reiterating what we're expecting on a full-year basis from a margin expansion perspective. It remains an area of focus for us. There's nothing really in the backlog that I'd call out that would drive a different view. We do continue to have a number of levers available to us to drive improvement across the board on margin. We've talked about those before. I think the growth of the business will continue to support that margin expansion expectation. On the restructuring, one of the areas that we expect to see is, we will have some cost savings from that. We would also expect to be able to reinvest some of those savings in higher growth areas of the business as well as in innovation. Anne CybulskiInterim CFO at ATS Corporation00:21:01Overall, a number of levers available to us to continue to drive towards that longer-term objective that you referenced. Sabahat KhanManaging Director of Global Research at RBC00:21:10Great. Just from a follow-up, I guess, as you think about sort of the inorganic side. Sounds like you guys are still sort of keeping your options open, but should we expect that to pick up in a more meaningful way when Larry sort of heads in that with a two-handle on it, or is that something you're sort of open to right now? If so, what are some of the end markets in focus as it relates to your pipeline? Thanks. Ryan McLeodInterim CEO at ATS Corporation00:21:33Good morning, Saba. Yeah, I mean, we're certainly very active in cultivating, reviewing opportunities. At the same time, we are, as Anne said in her prepared remarks, focused on bringing our leverage down. That provides us more flexibility. Cultivation does take time. We have seen good activity over the last several months in terms of what's happening in our funnel. I mean, we're going to be prudent in how we go forward here, certainly conscious of where we're trading right now. Equity remains an option for us. As I said, we're conscious of where we're trading right now. For the right deal and in the right circumstance, that certainly remains an option for us. Just to go back, the U.S. listing, one of the rationales there was that does make our shares more attractive as currency and M&A. Ryan McLeodInterim CEO at ATS Corporation00:22:43All of those options remain on the table. As I said, we do want to deleverage that. Ultimately, it provides us more flexibility. At the same time, there is an active market right now. We are going to find the right balance on both. Sabahat KhanManaging Director of Global Research at RBC00:22:59Great. Thanks very much. Operator00:23:02Your next question comes from the line of Maxim Sytchev from National Bank of Canada. Your line is open. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:23:10Hi, good morning, team. Ryan McLeodInterim CEO at ATS Corporation00:23:13Morning. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:23:13Ryan, I was wondering if it's possible to get a bit of your general sense on the healthcare space. I mean, we seem to be seeing more healthcare M&A as the pharma companies need to replace the pipelines. I guess how quickly can we see potentially sort of inflection point in terms of opportunities on that side, even though obviously you're quoting a pretty healthy funnel? Just curious around your general thoughts in relation to that. Thank you. Ryan McLeodInterim CEO at ATS Corporation00:23:42Yeah, good morning, Max. I mean, Max, I'll probably reiterate a little bit of what I said, but we are seeing good activity in our funnel. If I start with auto injector, and that's really the drug delivery format that's really being used with GLP-1 drugs, we're in the middle of executing some larger programs there. As I said, funnel activity is still encouraging, and some of that is tied to continued expansion of those drugs and consumer adoption, as well as some new therapies. I mentioned conditions such as cardiovascular health and neurological conditions, which are, there's research and trials ongoing to support GLP-1s as therapies for those conditions. All of that, we do expect to drive continued growth in the auto injector space. We're also working with customers on new technologies there. Ryan McLeodInterim CEO at ATS Corporation00:24:49A lot of the drug delivery today is single-use auto injectors. There is a move towards fixed dosage, multi-dose auto injectors. Rather than one-time use and throwing it away, it can be used for multiple injections. There is, as I said, a good funnel there and good activity. I think. Sorry, just equally. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:25:15I'm glad. Ryan McLeodInterim CEO at ATS Corporation00:25:15Yeah. The other area that I mentioned, but I'll spend a little bit more time on, is radiopharma. That's very active. There's a lot of drug discovery, drug development happening, customers moving from R&D into clinical trials, and then into commercial manufacturing. We've been winning projects in new diagnostics and therapeutic applications. There's a lot of activity happening in that space. It's very exciting. I talked in my prepared remarks about our Comecer Competence Center, which recently opened in Indianapolis. That really positions us well to provide regional support in North America, collaborate more closely with our customers, and have an improved service response time for customers in that region. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:26:09Yeah, that's great, color. Thank you so much. Maybe just a question in relation to nuclear. I'm not sure if Anne wants to take this one. In terms of, I mean, obviously, the backlog is up significantly in that space. How should we think about the tail of that backlog to revenue conversion? Is there anything different in relation to this project? Can you provide any more color there? Thank you. Anne CybulskiInterim CFO at ATS Corporation00:26:33Hi, Max. So yeah, we've seen good growth in terms of the nuclear backlog, as you said. A good chunk of the backlog is related to the reactor refurbishment or life extension programs that are primarily CANDU technology-driven. That said, there are a number of customers that we have also in the backlog that would represent our earlier participation from a design perspective in some of the new build work that is ongoing. It is a good cross-section of customers in terms of overall weighting of the backlog. We'd expect to see that refurbishment work continue over the next, say, call it a year and a half to two years at a minimum, and then be supplemented over the mid to longer term with some of the work that we're doing on the new builds. From an early participation standpoint on new builds, we're very active there. Anne CybulskiInterim CFO at ATS Corporation00:27:39That's important to the longer-term play. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:27:42Absolutely. Thank you so much. Operator00:27:46Your next question comes from a line of Justin Keywood from Stifel. Your line is open. Justin KeywoodManaging Director of Institutional Research at Stifel00:27:52Good morning. Thanks for taking my call. I'll start off with leverage. Does the target remain to exit this fiscal year at 3x? Anne CybulskiInterim CFO at ATS Corporation00:28:04Hi, Justin. Short answer is we do expect to come back within our targeted range by the end of the fiscal year. That's our goal. Justin KeywoodManaging Director of Institutional Research at Stifel00:28:14Okay. That suggests some healthy free cash flow generation in the next few quarters. Just circling back on the nuclear, just to drill down here, because in the backlog, it does show as the second largest segment, which is a bit surprising. I understand that some of these projects are longer-term in nature. How should we see that nuclear or energy segment as a percentage of revenue trending over the next year or over the next few years? Thank you. Ryan McLeodInterim CEO at ATS Corporation00:28:54Hey, Justin. I mean, the short answer is it's going to grow. I don't want to get too specific in terms of percentage of business, but as you noted, it's become a significant part of our backlog. The activity in that space and funnel activity is very healthy. We are working with a number of customers in the new build space in addition to the work that we continue to execute on in refurbishment. Decommissioning also is a growing space. There is a lot of opportunity, and it's an attractive growth opportunity for us. It will continue to grow, but I'm not going to put a percentage on it in terms of how big of a business it will be. Justin KeywoodManaging Director of Institutional Research at Stifel00:29:48Okay. Thank you. Those are my two questions. Operator00:29:52Again, if you'd like to ask a question, press star, then the number one, on your telephone keypad. Your next question comes from the line of Jonathan Goldman from Scotiabank. Your line is open. Jonathan GoldmanEquity Research Analyst at Scotiabank00:30:04Hi, good morning, team. Thanks for taking my questions. Maybe just on the backlog, when do you expect to last the large enterprise orders? Anne CybulskiInterim CFO at ATS Corporation00:30:15Just to make sure I heard your question, Jonathan, when do we expect to—can you repeat it? I did not hear you. Jonathan GoldmanEquity Research Analyst at Scotiabank00:30:21Cycle over the large enterprise orders from last year. I think that seems like a pretty clear reason why backlog is kind of stabilized or not growing as fast. I just want to know when you plan to lap those large tough comps from last year. Anne CybulskiInterim CFO at ATS Corporation00:30:36We are, as I said in my prepared remarks, executing on some of those larger orders that we did book in Q2 last year. There are a number of those that are still in progress, and we are getting into the later stages of them. That said, we continue to book new work. As Ryan talked about, the funnel is healthy. As we continue to execute on those larger programs, we would expect the backlog to fill in with new work. Jonathan GoldmanEquity Research Analyst at Scotiabank00:31:14Remind me, I think the larger enterprise orders have a longer delivery period beyond 12 months. Is that correct? Anne CybulskiInterim CFO at ATS Corporation00:31:20Yes, that's right. They tend to run more in the 12-18 month range and sometimes up to 24. Jonathan GoldmanEquity Research Analyst at Scotiabank00:31:27Okay, perfect. I guess the second one for me on the working cap, what's the visibility or maybe what gives you confidence as we sit here today that you can hit the 15% target this year? I don't know if that's an exit rate for the year totally, but what do you think needs to happen to get there? Anne CybulskiInterim CFO at ATS Corporation00:31:47There are obviously things that could affect that from a timing perspective. The main piece of that would be related to timing of milestone billings and then collection on some of those larger opportunities. As we continue to work through that backlog, we would expect improvement by the end of the year. Throughout Q3, I would say we'll still see that higher working capital need on some of those larger programs. Overall, our objective remains 15%. There are opportunities across the business to drive working capital efficiency, including some of our more recently acquired businesses that came on board with a heavier working capital intensity. Overall, business is focused on this, but those are the factors that'll drive the improvement by the end of the year. Jonathan GoldmanEquity Research Analyst at Scotiabank00:32:43Okay. That's good color. Thanks for taking my questions. Anne CybulskiInterim CFO at ATS Corporation00:32:46You're welcome. Operator00:32:48Your next question comes from a line of Patrick Baumann from JPMorgan. Your line is open. Patrick BaumannAnalyst at JPMorgan00:32:55Hi, good morning. I had a couple of questions here. One is on life sciences. Any reason why the revenue seems to be coming in a little bit slow? There. Just wondering if there's hesitation at all related to some of the order backlog that's been built there related to government policy and things of that nature? Ryan McLeodInterim CEO at ATS Corporation00:33:17Good morning, Patrick. I mean, the short answer is no. It's largely timing on execution of projects in our backlog that drives the bulk of our revenue conversion. As I said in my prepared remarks, we do have some exposure to publicly funded institutions, organizations within the lab space, but it's a small part of our business. I mean, if we step back on that, a couple of years ago or even last year, China was weak, and we've actually seen that improve in that part of the business. Now, this year, with some of those funding changes, that's created headwinds in North America. As I said, it's a small piece of our overall business. We're actually, I think I mentioned this in my prepared remarks as well, we're in the process of. Ryan McLeodInterim CEO at ATS Corporation00:34:20Doing some joint go-to-market approaches across our lab businesses to share customer lists and how we're approaching customers in certain geographies. Early days of that initiative, but we do expect that'll provide some offset to some of the funding challenges that do exist within the U.S. Patrick BaumannAnalyst at JPMorgan00:34:42Got it. I guess I missed maybe the first part of the Q&A. Did you comment on how you think margins will trend sequentially in the third quarter and then also the CAD 15 million of restructuring? What's that targeted at? Anne CybulskiInterim CFO at ATS Corporation00:34:59Hi, Patrick. Yes, I did briefly mention it. Just to recap, when we think about the margin trajectory for the back half of the year, we do expect to see full-year margin expansion. That is consistent with what we have said previously. On the restructuring, the benefit of that as we execute on those initiatives will flow into—there will be some cost savings that we will see as part of our overall margin expansion efforts. There is also an opportunity for us to reinvest some of those savings in higher growth areas of the business. Ryan had flagged energy and nuclear as a growth area. We also continue to focus on innovation, and that has really been a core of our strategy and a key to our success over the years. Patrick BaumannAnalyst at JPMorgan00:36:03Thanks. If you don't want to comment on quarterly trajectory, remind me what the annual margin expansion target was. Anne CybulskiInterim CFO at ATS Corporation00:36:13We did not peg a specific number, but we did say we were expecting to see year-over-year margin expansion compared to last year. Last year, we were at, from an adjusted EBITDA perspective, 13.8%. So better than that by the end of the year through continuing to execute on the projects we have got in our backlog and driving some of the efficiencies that we have talked about through the levers that we have available to us. Patrick BaumannAnalyst at JPMorgan00:36:40On the high single-digit revenue growth guidance that was reaffirmed for the year, can you remind me if that is organic revenue or if it is total revenue? Anne CybulskiInterim CFO at ATS Corporation00:36:51It is total revenue. We do have in our year-to-date numbers some M&A benefit. Barring any further M&A in the back half of the year, which we do not build into our guidance, there would be no M&A benefit in the back half of the year. The FX rates will do what the FX rates are going to do. We do still expect that high single-digit growth top line that would include continued organic growth. Patrick BaumannAnalyst at JPMorgan00:37:24That includes FX as well and M&A? Anne CybulskiInterim CFO at ATS Corporation00:37:28From the first half, yeah. The M&A from the first half. Operator00:37:34Your next question comes from a line of Michael Glen from Raymond James. Your line is open. Michael GlenManaging Director at Raymond James00:37:41Hey, good morning. Ryan, are you able to comment on what the customer feedback is with the oral application for GLP-1s? Are you seeing this impact your funnel, or is it raising any concerns as to how this may impact future orders for auto injector? Ryan McLeodInterim CEO at ATS Corporation00:38:01Good morning, Michael. Customers in this space, they are working to develop an oral alternative. I think that really stems from the belief that that'll drive wider consumer adoption versus an injectable. To date, a lot of the studies and the development work, there's been some challenges with that, some of it tied to the patient experience causing nausea. There's a tolerability trade-off. There's also been some challenges around the active ingredients and how they get absorbed into the system. Nevertheless, I do expect that's going to continue to be a focus area for customers. To date, and as we see it, auto injectors really remain, and direct injection really remain, the most reliable, effective, and widely adopted delivery format for these GLP-1 drugs. Oral formulations could certainly become a complement to that if you get into maintenance phases, as an example. Ryan McLeodInterim CEO at ATS Corporation00:39:24We continue to see that auto injectors will have a very prominent place in drug delivery for GLP-1 therapies. Michael GlenManaging Director at Raymond James00:39:34Okay. Can you remind us, I believe in the past you've indicated that GLP-1 was roughly 20% of the life science backlog? Are you able to give an update on where that figure sits today? Ryan McLeodInterim CEO at ATS Corporation00:39:49Yeah, it's still in that range. Michael GlenManaging Director at Raymond James00:39:52Okay. And then last one for me. Just looking at the SG&A. For the overall business, and I believe you gave the CAD 134.6 million figure as the run rate ex-share-based comps, is this the right level for—at this point in time, should we start to see leverage on SG&A? Should SG&A on that adjusted basis grow slower than overall revenue growth? Anne CybulskiInterim CFO at ATS Corporation00:40:23That's the goal. As part of our margin expansion focus internally, we do have a focus on SG&A. As the top line grows, I would expect to see that improved leverage drop through. Michael GlenManaging Director at Raymond James00:40:42Okay. Thank you. Operator00:40:46That concludes our question and answer session. I will now turn the call back over to Ryan McLeod for some final closing remarks. Ryan McLeodInterim CEO at ATS Corporation00:40:54Great. Thank you, operator. Thank you, everyone, for joining us today. We look forward to speaking to you on our third quarter call in February. Operator00:41:02This concludes today's conference call. Thank you for your participation. You may now disconnect.Read moreParticipantsExecutivesDavid OcampoHead of IRAnne CybulskiInterim CFORyan McLeodInterim CEOAnalystsJonathan GoldmanEquity Research Analyst at ScotiabankCherilyn RadbourneManaging Director of Equity Research at TD CowenMaxim SytchevManaging Director of Research in Industrial Products at National Bank of CanadaPatrick BaumannAnalyst at JPMorganSabahat KhanManaging Director of Global Research at RBCJustin KeywoodManaging Director of Institutional Research at StifelMichael GlenManaging Director at Raymond JamesPowered by Earnings DocumentsSlide DeckEarnings Release ATS Q2 2026 Earnings FAQ Did ATS beat earnings estimates for Q2 2026? ATS (NYSE:ATS) reported earnings of $0.33 per share for Q2 2026, beating the consensus estimate of $0.31. The report was announced on Wednesday, November 5, 2025. What was ATS' revenue for Q2 2026? ATS reported revenue of $524.03 million for Q2 2026, against a consensus estimate of $721.51 million. Where can I read ATS' Q2 2026 earnings call transcript? The full ATS Q2 2026 earnings conference call transcript is published on this page, including prepared remarks and the analyst Q&A session, along with the participants who spoke on the call. When is ATS' next earnings date? ATS' next earnings date is estimated for Wednesday, February 3, 2027. MarketBeat tracks confirmed and estimated earnings dates for ATS on the company's earnings history page. ATS Earnings HeadlinesThe New York Stock Exchange Will Soon Use Avalanche for Tokenized Stocks. Is the Coin a Screaming Buy Right Now?November 17 at 6:30 AM | fool.comHaryana ATS arrests 2 more in narco-terror case; tally rises to nineNovember 16 at 7:05 PM | msn.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027. | OilPrice (Ad)ATS Executives Scheduled to Participate in Baird Industrial ConferenceNovember 16 at 5:11 PM | tipranks.comATS Corporation Announces Participation in Scotiabank Transportation & Industrials ConferenceNovember 16 at 5:11 PM | tipranks.comATS links Kanpur man to bomb threat to Diljit’s Indore concert, Gwalior courtNovember 12, 2026 | msn.comSee More ATS Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ATS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ATS and other key companies, straight to your email. Email Address About ATSATS (NYSE:ATS) designs, builds and services automated manufacturing systems for companies seeking to improve production processes. Its offerings include custom automation equipment, robotics, assembly and testing systems, and related software and services. The company serves customers across a range of industries, including life sciences, food and beverage, transportation, consumer products and energy. Its work can span the manufacturing lifecycle, from system design and integration to installation, maintenance and upgrades. Based in Cambridge, Ontario, ATS has a history of developing automation solutions and serves customers internationally through operations in multiple regions. The company was formerly known as ATS Automation Tooling Systems.View ATS ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Welcome to the ATS Corporation second quarter conference call and webcast. This call is being recorded on November 5th, 2025, at 8:30 A.M. Eastern Time. Following the presentation, we will conduct a question-and-answer session. I'd now like to turn the call over to David Ocampo, Head of Investor Relations at ATS. David OcampoHead of IR at ATS Corporation00:00:22Thank you, Operator, and good morning, everyone. On the call today are Ryan McLeod, Interim Chief Executive Officer of ATS, and Anne Cybulski, Interim Chief Financial Officer. Please note that our remarks today are accompanied by a slide deck, which can be viewed via our webcast and available at atsautomation.com. We caution that the statements made on the webcast and conference call may contain forward-looking information and are a cautionary statement regarding such information, including the material factors that could cause actual results to differ materially from the statements, and the material factors or assumptions applied in making the statements are detailed in slide three of the slide deck. Now it's my pleasure to turn the call over to Ryan. Ryan McLeodInterim CEO at ATS Corporation00:01:05Thank you, David, and welcome to ATS. It's great to have you on the team. Good morning, everyone, and thank you for joining us today. Today, ATS reported second quarter results for fiscal 2026, highlighted by strong organic revenue growth and an improvement in adjusted earnings margins in line with our expectations. These results reflect the strength of our decentralized organization and the collective efforts of our teams. During this leadership transition period, it is business as usual as we build on our culture of continuous improvement through the ATS Business Model, with a clear focus on creating value across our diversified global portfolio. As we've previously discussed, the board began its search for a permanent CEO over the summer and is now well into the process. While our entire senior leadership team remains intensely focused on advancing our strategic growth priorities. Ryan McLeodInterim CEO at ATS Corporation00:02:00This morning, I will update you on the business and our markets, and Anne will provide her financial report. Starting with our financial value drivers, order bookings were CAD 734 million, up 6% sequentially, reflecting solid performance and strength across our diversified end markets. Q2 revenues were CAD 729 million, up 19% from Q2 last year, driven primarily by organic growth and supported by solid performance and services. Adjusted earnings from operations in Q2 were CAD 79 million. Moving to our outlook, order backlog of approximately CAD 2.1 billion continues to provide good revenue visibility. Our opportunity funnel remains healthy and well-diversified. Within life sciences, order backlog at quarter end remains strong at CAD 1.1 billion. Supported by demand across sub-markets. Importantly, the wider life sciences funnel includes a mix of opportunities in radiopharma, auto injectors, diagnostic wearables, and automated pharmacies. Ryan McLeodInterim CEO at ATS Corporation00:03:10ATS works with a broad set of leading GLP-1 customers, providing diversification across platforms and drug delivery formats. In addition, as other applications for GLP-1 therapies emerge, including for treatment of cardiovascular and neurological disorders, ATS is well-positioned to support providers of drug delivery solutions. Momentum remains especially strong in the radiopharma space, supported by investments in production capacity and the advancement of new therapeutics. To support growth and meet evolving customer needs, our recently opened Comecer Competence Center in Indianapolis delivers enhanced service capabilities and faster response times for customers in North America. During the quarter, Comecer secured new wins in diagnostic and therapeutic projects, advancing next-generation capabilities for radiopharmaceutical production. Within the lab research space, government-funded customers continue to take a more measured approach to capital investment, given the changing U.S. funding environment. Ryan McLeodInterim CEO at ATS Corporation00:04:16While orders from these customers represent a small portion of our overall business, our lab equipment businesses have been leveraging the common ABM framework to improve joint commercial initiatives and to expand shared access to their individual customer bases. In food and beverage, quarter-end backlog was CAD 218 million, with customer wins in multiple regions during Q2 in primary processing and in sorting and inspection, supported by internally developed products and technology. Our food and beverage funnel remains strong, with customer investment focused on automation that enhances yield, quality, and energy efficiency across our comprehensive solutions, spanning primary processing, inspection, primary and secondary packaging, and aftermarket support. In energy, order backlog was a record CAD 277 million, up 154% over Q2 last year. This increase was driven primarily by nuclear refurbishment projects as operators continued to invest in life extension programs. Ryan McLeodInterim CEO at ATS Corporation00:05:25The nuclear funnel continues to broaden beyond refurbishment, covering service and new nuclear reactor builds, including small modular reactors. On new builds, initial activity centers on early-phase design and engineering programs that support modular fabrication of reactor structures and fuel handling systems. These programs position ATS to participate as projects move into commercial deployment. While order timing may vary, supportive policies and growing demand for clean and reliable energy, including from data centers, support a strong outlook for nuclear. In consumer products, our funnel remains stable, with ongoing programs in personal care and household goods packaging, along with warehouse automation. In transportation, the funnel consists of relatively smaller opportunities consistent with our expectations. Our capabilities in battery assembly allow us to win and deliver on these opportunities as they arise. Ryan McLeodInterim CEO at ATS Corporation00:06:28Overall, our balanced exposure to regulated and growth-oriented end markets, along with a strong order backlog, positions us well to navigate the current environment. Turning to the ATS business model, it remains central to how we operate and is well embedded into our culture. I recently attended our Global ABM Conference, where our continuous improvement leaders from across the business demonstrated their commitment to driving the ABM, along with a renewed focus on creating impact for customers and shareholders through disciplined execution and operational efficiency. I continue to be impressed by our team's use of the ABM to drive value within their operations. This includes daily visual management tools to create immediate focus and drive problem-solving, as well as sustained process improvements through Kaizen and strategy deployment. On M&A, our funnel is healthy and active as we cultivate and review opportunities that align with our long-term strategic priorities. Ryan McLeodInterim CEO at ATS Corporation00:07:31We continue to integrate our more recent acquisitions and drive further synergies, particularly through shared customer access and integrated offerings from across our portfolio. We're also working diligently to return leverage to within our target range, with good progress made during the quarter. On innovation, we have further developed our Illuminate Manufacturing Intelligence platform to support new deployments at select businesses, including some of our more recent acquisitions. These efforts allow us to efficiently integrate equipment, standardize data capture and analytics, and improve visibility across our installed base. The 2025 ATS Innovation Summit is being held this week, bringing together key innovation leaders from across the ATS organization. Through panels and workshops, the summit seeks to foster a unified innovation ecosystem, accelerate product development, and strengthen collaboration on translating emerging technologies into customer value. Ryan McLeodInterim CEO at ATS Corporation00:08:31Our investment in innovation has been core to our strategy and remains a key differentiator for ATS. In summary, our results this quarter reflect good progress across our value drivers, supported by a strong backlog. Our advantages today, including our global footprint, our talented workforce aligned around our ABM culture, and our strong customer relationships, will serve us well to advancing our growth and long-term value creation strategy for the future. Now, I will turn the call over to Anne. Anne, over to you. Anne CybulskiInterim CFO at ATS Corporation00:09:05Thank you, Ryan, and good morning, everyone. Starting with our operating results for the quarter, order bookings were CAD 734 million, down 1.1% compared to Q2 last year, which included several larger enterprise bookings in life sciences. This was largely offset by growth in all other markets over last year. Our trailing 12-month book-to-bill ratio at the end of Q2 remained healthy at 1.12x to 1x and was at or above 1x across all market verticals. Revenues for the second quarter were CAD 729 million, up 18.9% compared to last year, including organic growth of 12.6%, along with a 3.9% benefit from foreign exchange translation and a 2.4% contribution from acquisitions. Moving to earnings, second quarter adjusted earnings from operations were CAD 79.1 million, a 40% increase from prior year, primarily on higher revenue volumes. Gross margin for Q2 was 29.9%, a 36 basis point increase on Q2 last year. Anne CybulskiInterim CFO at ATS Corporation00:10:15On SG&A, excluding acquisition-related amortization and transaction costs, expenses in the first quarter totaled CAD 134.5 million. A CAD 14.5 million increase over the prior year, primarily a result of incremental SG&A from acquired companies and FX translation impact. Excluding a recovery related to forfeitures from our former CEO's departure and mark-to-market impact related to changes in our share price, stock-based compensation expense was CAD 4.3 million in Q2. Earnings per share were CAD 0.45 on an adjusted basis. Moving to our outlook, we ended the quarter with an order backlog of approximately CAD 2.1 billion. Q3 revenues are expected to be in the range of CAD 700 million-CAD 740 million. As a reminder, this assessment is updated every quarter, taking into account revenue expectations from current order backlog and new orders booked and billed within the quarter. Anne CybulskiInterim CFO at ATS Corporation00:11:19This quarter, we have identified an opportunity to realign our cost structure to strategic focus areas and to drive global operational efficiencies. We estimate restructuring costs of approximately CAD 15 million will be incurred in the final half of this fiscal year, with an expected payback of less than one year. For clarity, there is no change to our expectations for full-year high single-digit revenue growth as previously disclosed. We continue to expect adjusted operating margin improvement on a full-year basis in fiscal 2026. ABM discipline and tools help to create focus across all of our value drivers, including margin expansion. The macro environment remains dynamic, including geopolitical tensions and trade and tariff considerations. As a reminder, the majority of our exports from Canada into the U.S. remain covered under the USMCA. Anne CybulskiInterim CFO at ATS Corporation00:12:15Our global and decentralized operating model positions us well to navigate market dynamics to serve customers where they are deploying capital. In this environment, ATS continues to execute well, maintaining leadership in our key sub-markets and driving progress on our growth priorities. Moving to the balance sheet. In Q2, cash flows from operating activities were CAD 28 million. Our non-cash working capital as a percentage of revenues was 18.3%. While timing of milestone billings and collections do impact this percentage, our focus on driving working capital efficiency across the business and our target of 15% remains unchanged. We expect to see improvement by the end of the fiscal year. During the quarter, we invested CAD 18.3 million in CapEx and intangible assets, reflecting our disciplined focus on innovation and strengthening our capabilities. Anne CybulskiInterim CFO at ATS Corporation00:13:14For fiscal 2026, we expect our CapEx and intangible investment to be within our previously disclosed range of CAD 80 million-CAD 100 million. On leverage, our net debt-to-adjusted EBITDA ratio was 3.4x. This progress since the beginning of the year supports our expectation of reducing leverage to within our target range of 2x-3x. In summary, we're pleased with second quarter results and with the alignment of our leadership team and global employee base as we continue to execute on our plans and drive the business forward. Our strong order backlog supports our outlook for sustained growth, and our expectations for revenue and margin expansion in fiscal 2026 are unchanged. ATS is leveraging our culture of continuous improvement and our embedded structural advantages to drive tangible value through a consistent, disciplined approach. Anne CybulskiInterim CFO at ATS Corporation00:14:11We are confident that our team's continued efforts will deliver value to both our customers and shareholders. Now, we will open the call to questions from our analysts. Operator, could you please provide instructions? Thank you. Operator00:14:25Thank you. We will now begin the question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. If you would like to withdraw your question, simply press star one again. We ask that you please limit yourself to two questions only. You may re-queue for any further questions. Your first question today comes from the line of Cherilyn Radbourne from TD Cowen. Your line is open. Cherilyn RadbourneManaging Director of Equity Research at TD Cowen00:14:49Thanks very much and good morning. When we look at your results, the one thing that is of some concern to us is that it appears bookings momentum has slowed over the last six months relative to the second half of last year. Just curious, what gives you confidence that that's just normal lumpiness in the business and not something more? Ryan McLeodInterim CEO at ATS Corporation00:15:13Hi, good morning, Cherilyn. So, I mean, a couple of things. First of all, I mean, when we look at the state of the business. There is normal course variability, and there are some larger programs which can really drive that. Our book-to-bill is healthy at 1.12x. From a backlog perspective, we're up about 14%, 13.5%, 14% year-over-year. We are in a really good position from a backlog standpoint. I think, importantly to your question. Funnel activity, and I talked about it a little bit in my prepared remarks, but in general, is healthy across our vertical markets. Life sciences, really good activity. Auto injectors remain very active. We're seeing a lot of activity in radiopharma as well as medical, general medical device wearables, contact lenses, automated pharmacy. A lot of activity across life sciences, which supports that outlook. Food continues to be strong. Ryan McLeodInterim CEO at ATS Corporation00:16:22We're seeing some really good uptake and interest based on what we're doing in primary processing, packaging, as well as some of the inspection and sorting capability that we have. Consumer stable, it's been very resilient. In transportation, as we expected, it's lower relative to where it was a couple of years ago, but there's still opportunities that are arising. I think the other area that we're seeing a lot of growth opportunity in is energy, and there's a lot happening. Refurbishment has continued to be active. We're seeing good activity in decommissioning and maybe a bit more mid to long term, but certainly accelerating, is the new nuclear space. Ryan McLeodInterim CEO at ATS Corporation00:17:11New builds, whether it's conventional technology or SMRs, we're seeing a lot of activity in that space and participating in a lot of early-stage projects to support the ongoing build-out that's going to be coming in the nuclear space. Overall, I mean, as I said, our funnels were very positive in terms of where they sit and support the continued growth that we expect. Cherilyn RadbourneManaging Director of Equity Research at TD Cowen00:17:40Okay, that's helpful, color. Just specifically, how did the services business perform in the second quarter? Along with that, are you intending to recruit someone to replace Simon Roberts to head that segment? Anne CybulskiInterim CFO at ATS Corporation00:17:58Hi, Cherilyn. I'll start with the numbers question. Overall, we're happy with the performance of the service business in the quarter, also on a year-to-date basis. I would call the performance strong. There were some EV numbers in the comparatives, but really good performance across other areas of the business. Services, as you know, are kind of recurring in nature. We have some in the numbers that are like upgrades that are less regular, but services remain strategic to our overall growth plans. Good performance, happy with what we're seeing across the business. I'll let Ryan comment on the other piece. Ryan McLeodInterim CEO at ATS Corporation00:18:43Yeah. Cherilyn, the short answer is yes. I mean, first of all, we're very pleased that Simon has taken on the leadership role within our packaging and food tech business. Simon's a longtime ATS executive, very experienced, knows the business very well. After sales is an attractive opportunity within packaging and food tech. Very well aligned with some of Simon's background. We will be replacing that role, yes. Cherilyn RadbourneManaging Director of Equity Research at TD Cowen00:19:19That's my two. Thank you. Ryan McLeodInterim CEO at ATS Corporation00:19:21Thank you. Operator00:19:23Your next question comes from a line of Sabahat Khan from RBC. Your line is open. Sabahat KhanManaging Director of Global Research at RBC00:19:29Great. Thanks for the good morning. I guess just looking ahead to sort of the back half of this year and to fiscal 2027, as you think about the margin trajectory. Do you think at this point in the cycle, do you think it's more driven by some incremental initiatives you need to take on the cost reduction side? I know you're now restructuring a little bit this morning. Or is it more from sales picking up on a more consistent basis over the next four to six quarters that sort of gets you moving towards the medium to longer-term targets you have on the margin side? Thanks. Anne CybulskiInterim CFO at ATS Corporation00:19:58Hi, good morning, Saba. Let me start with just reiterating what we're expecting on a full-year basis from a margin expansion perspective. It remains an area of focus for us. There's nothing really in the backlog that I'd call out that would drive a different view. We do continue to have a number of levers available to us to drive improvement across the board on margin. We've talked about those before. I think the growth of the business will continue to support that margin expansion expectation. On the restructuring, one of the areas that we expect to see is, we will have some cost savings from that. We would also expect to be able to reinvest some of those savings in higher growth areas of the business as well as in innovation. Anne CybulskiInterim CFO at ATS Corporation00:21:01Overall, a number of levers available to us to continue to drive towards that longer-term objective that you referenced. Sabahat KhanManaging Director of Global Research at RBC00:21:10Great. Just from a follow-up, I guess, as you think about sort of the inorganic side. Sounds like you guys are still sort of keeping your options open, but should we expect that to pick up in a more meaningful way when Larry sort of heads in that with a two-handle on it, or is that something you're sort of open to right now? If so, what are some of the end markets in focus as it relates to your pipeline? Thanks. Ryan McLeodInterim CEO at ATS Corporation00:21:33Good morning, Saba. Yeah, I mean, we're certainly very active in cultivating, reviewing opportunities. At the same time, we are, as Anne said in her prepared remarks, focused on bringing our leverage down. That provides us more flexibility. Cultivation does take time. We have seen good activity over the last several months in terms of what's happening in our funnel. I mean, we're going to be prudent in how we go forward here, certainly conscious of where we're trading right now. Equity remains an option for us. As I said, we're conscious of where we're trading right now. For the right deal and in the right circumstance, that certainly remains an option for us. Just to go back, the U.S. listing, one of the rationales there was that does make our shares more attractive as currency and M&A. Ryan McLeodInterim CEO at ATS Corporation00:22:43All of those options remain on the table. As I said, we do want to deleverage that. Ultimately, it provides us more flexibility. At the same time, there is an active market right now. We are going to find the right balance on both. Sabahat KhanManaging Director of Global Research at RBC00:22:59Great. Thanks very much. Operator00:23:02Your next question comes from the line of Maxim Sytchev from National Bank of Canada. Your line is open. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:23:10Hi, good morning, team. Ryan McLeodInterim CEO at ATS Corporation00:23:13Morning. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:23:13Ryan, I was wondering if it's possible to get a bit of your general sense on the healthcare space. I mean, we seem to be seeing more healthcare M&A as the pharma companies need to replace the pipelines. I guess how quickly can we see potentially sort of inflection point in terms of opportunities on that side, even though obviously you're quoting a pretty healthy funnel? Just curious around your general thoughts in relation to that. Thank you. Ryan McLeodInterim CEO at ATS Corporation00:23:42Yeah, good morning, Max. I mean, Max, I'll probably reiterate a little bit of what I said, but we are seeing good activity in our funnel. If I start with auto injector, and that's really the drug delivery format that's really being used with GLP-1 drugs, we're in the middle of executing some larger programs there. As I said, funnel activity is still encouraging, and some of that is tied to continued expansion of those drugs and consumer adoption, as well as some new therapies. I mentioned conditions such as cardiovascular health and neurological conditions, which are, there's research and trials ongoing to support GLP-1s as therapies for those conditions. All of that, we do expect to drive continued growth in the auto injector space. We're also working with customers on new technologies there. Ryan McLeodInterim CEO at ATS Corporation00:24:49A lot of the drug delivery today is single-use auto injectors. There is a move towards fixed dosage, multi-dose auto injectors. Rather than one-time use and throwing it away, it can be used for multiple injections. There is, as I said, a good funnel there and good activity. I think. Sorry, just equally. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:25:15I'm glad. Ryan McLeodInterim CEO at ATS Corporation00:25:15Yeah. The other area that I mentioned, but I'll spend a little bit more time on, is radiopharma. That's very active. There's a lot of drug discovery, drug development happening, customers moving from R&D into clinical trials, and then into commercial manufacturing. We've been winning projects in new diagnostics and therapeutic applications. There's a lot of activity happening in that space. It's very exciting. I talked in my prepared remarks about our Comecer Competence Center, which recently opened in Indianapolis. That really positions us well to provide regional support in North America, collaborate more closely with our customers, and have an improved service response time for customers in that region. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:26:09Yeah, that's great, color. Thank you so much. Maybe just a question in relation to nuclear. I'm not sure if Anne wants to take this one. In terms of, I mean, obviously, the backlog is up significantly in that space. How should we think about the tail of that backlog to revenue conversion? Is there anything different in relation to this project? Can you provide any more color there? Thank you. Anne CybulskiInterim CFO at ATS Corporation00:26:33Hi, Max. So yeah, we've seen good growth in terms of the nuclear backlog, as you said. A good chunk of the backlog is related to the reactor refurbishment or life extension programs that are primarily CANDU technology-driven. That said, there are a number of customers that we have also in the backlog that would represent our earlier participation from a design perspective in some of the new build work that is ongoing. It is a good cross-section of customers in terms of overall weighting of the backlog. We'd expect to see that refurbishment work continue over the next, say, call it a year and a half to two years at a minimum, and then be supplemented over the mid to longer term with some of the work that we're doing on the new builds. From an early participation standpoint on new builds, we're very active there. Anne CybulskiInterim CFO at ATS Corporation00:27:39That's important to the longer-term play. Maxim SytchevManaging Director of Research in Industrial Products at National Bank of Canada00:27:42Absolutely. Thank you so much. Operator00:27:46Your next question comes from a line of Justin Keywood from Stifel. Your line is open. Justin KeywoodManaging Director of Institutional Research at Stifel00:27:52Good morning. Thanks for taking my call. I'll start off with leverage. Does the target remain to exit this fiscal year at 3x? Anne CybulskiInterim CFO at ATS Corporation00:28:04Hi, Justin. Short answer is we do expect to come back within our targeted range by the end of the fiscal year. That's our goal. Justin KeywoodManaging Director of Institutional Research at Stifel00:28:14Okay. That suggests some healthy free cash flow generation in the next few quarters. Just circling back on the nuclear, just to drill down here, because in the backlog, it does show as the second largest segment, which is a bit surprising. I understand that some of these projects are longer-term in nature. How should we see that nuclear or energy segment as a percentage of revenue trending over the next year or over the next few years? Thank you. Ryan McLeodInterim CEO at ATS Corporation00:28:54Hey, Justin. I mean, the short answer is it's going to grow. I don't want to get too specific in terms of percentage of business, but as you noted, it's become a significant part of our backlog. The activity in that space and funnel activity is very healthy. We are working with a number of customers in the new build space in addition to the work that we continue to execute on in refurbishment. Decommissioning also is a growing space. There is a lot of opportunity, and it's an attractive growth opportunity for us. It will continue to grow, but I'm not going to put a percentage on it in terms of how big of a business it will be. Justin KeywoodManaging Director of Institutional Research at Stifel00:29:48Okay. Thank you. Those are my two questions. Operator00:29:52Again, if you'd like to ask a question, press star, then the number one, on your telephone keypad. Your next question comes from the line of Jonathan Goldman from Scotiabank. Your line is open. Jonathan GoldmanEquity Research Analyst at Scotiabank00:30:04Hi, good morning, team. Thanks for taking my questions. Maybe just on the backlog, when do you expect to last the large enterprise orders? Anne CybulskiInterim CFO at ATS Corporation00:30:15Just to make sure I heard your question, Jonathan, when do we expect to—can you repeat it? I did not hear you. Jonathan GoldmanEquity Research Analyst at Scotiabank00:30:21Cycle over the large enterprise orders from last year. I think that seems like a pretty clear reason why backlog is kind of stabilized or not growing as fast. I just want to know when you plan to lap those large tough comps from last year. Anne CybulskiInterim CFO at ATS Corporation00:30:36We are, as I said in my prepared remarks, executing on some of those larger orders that we did book in Q2 last year. There are a number of those that are still in progress, and we are getting into the later stages of them. That said, we continue to book new work. As Ryan talked about, the funnel is healthy. As we continue to execute on those larger programs, we would expect the backlog to fill in with new work. Jonathan GoldmanEquity Research Analyst at Scotiabank00:31:14Remind me, I think the larger enterprise orders have a longer delivery period beyond 12 months. Is that correct? Anne CybulskiInterim CFO at ATS Corporation00:31:20Yes, that's right. They tend to run more in the 12-18 month range and sometimes up to 24. Jonathan GoldmanEquity Research Analyst at Scotiabank00:31:27Okay, perfect. I guess the second one for me on the working cap, what's the visibility or maybe what gives you confidence as we sit here today that you can hit the 15% target this year? I don't know if that's an exit rate for the year totally, but what do you think needs to happen to get there? Anne CybulskiInterim CFO at ATS Corporation00:31:47There are obviously things that could affect that from a timing perspective. The main piece of that would be related to timing of milestone billings and then collection on some of those larger opportunities. As we continue to work through that backlog, we would expect improvement by the end of the year. Throughout Q3, I would say we'll still see that higher working capital need on some of those larger programs. Overall, our objective remains 15%. There are opportunities across the business to drive working capital efficiency, including some of our more recently acquired businesses that came on board with a heavier working capital intensity. Overall, business is focused on this, but those are the factors that'll drive the improvement by the end of the year. Jonathan GoldmanEquity Research Analyst at Scotiabank00:32:43Okay. That's good color. Thanks for taking my questions. Anne CybulskiInterim CFO at ATS Corporation00:32:46You're welcome. Operator00:32:48Your next question comes from a line of Patrick Baumann from JPMorgan. Your line is open. Patrick BaumannAnalyst at JPMorgan00:32:55Hi, good morning. I had a couple of questions here. One is on life sciences. Any reason why the revenue seems to be coming in a little bit slow? There. Just wondering if there's hesitation at all related to some of the order backlog that's been built there related to government policy and things of that nature? Ryan McLeodInterim CEO at ATS Corporation00:33:17Good morning, Patrick. I mean, the short answer is no. It's largely timing on execution of projects in our backlog that drives the bulk of our revenue conversion. As I said in my prepared remarks, we do have some exposure to publicly funded institutions, organizations within the lab space, but it's a small part of our business. I mean, if we step back on that, a couple of years ago or even last year, China was weak, and we've actually seen that improve in that part of the business. Now, this year, with some of those funding changes, that's created headwinds in North America. As I said, it's a small piece of our overall business. We're actually, I think I mentioned this in my prepared remarks as well, we're in the process of. Ryan McLeodInterim CEO at ATS Corporation00:34:20Doing some joint go-to-market approaches across our lab businesses to share customer lists and how we're approaching customers in certain geographies. Early days of that initiative, but we do expect that'll provide some offset to some of the funding challenges that do exist within the U.S. Patrick BaumannAnalyst at JPMorgan00:34:42Got it. I guess I missed maybe the first part of the Q&A. Did you comment on how you think margins will trend sequentially in the third quarter and then also the CAD 15 million of restructuring? What's that targeted at? Anne CybulskiInterim CFO at ATS Corporation00:34:59Hi, Patrick. Yes, I did briefly mention it. Just to recap, when we think about the margin trajectory for the back half of the year, we do expect to see full-year margin expansion. That is consistent with what we have said previously. On the restructuring, the benefit of that as we execute on those initiatives will flow into—there will be some cost savings that we will see as part of our overall margin expansion efforts. There is also an opportunity for us to reinvest some of those savings in higher growth areas of the business. Ryan had flagged energy and nuclear as a growth area. We also continue to focus on innovation, and that has really been a core of our strategy and a key to our success over the years. Patrick BaumannAnalyst at JPMorgan00:36:03Thanks. If you don't want to comment on quarterly trajectory, remind me what the annual margin expansion target was. Anne CybulskiInterim CFO at ATS Corporation00:36:13We did not peg a specific number, but we did say we were expecting to see year-over-year margin expansion compared to last year. Last year, we were at, from an adjusted EBITDA perspective, 13.8%. So better than that by the end of the year through continuing to execute on the projects we have got in our backlog and driving some of the efficiencies that we have talked about through the levers that we have available to us. Patrick BaumannAnalyst at JPMorgan00:36:40On the high single-digit revenue growth guidance that was reaffirmed for the year, can you remind me if that is organic revenue or if it is total revenue? Anne CybulskiInterim CFO at ATS Corporation00:36:51It is total revenue. We do have in our year-to-date numbers some M&A benefit. Barring any further M&A in the back half of the year, which we do not build into our guidance, there would be no M&A benefit in the back half of the year. The FX rates will do what the FX rates are going to do. We do still expect that high single-digit growth top line that would include continued organic growth. Patrick BaumannAnalyst at JPMorgan00:37:24That includes FX as well and M&A? Anne CybulskiInterim CFO at ATS Corporation00:37:28From the first half, yeah. The M&A from the first half. Operator00:37:34Your next question comes from a line of Michael Glen from Raymond James. Your line is open. Michael GlenManaging Director at Raymond James00:37:41Hey, good morning. Ryan, are you able to comment on what the customer feedback is with the oral application for GLP-1s? Are you seeing this impact your funnel, or is it raising any concerns as to how this may impact future orders for auto injector? Ryan McLeodInterim CEO at ATS Corporation00:38:01Good morning, Michael. Customers in this space, they are working to develop an oral alternative. I think that really stems from the belief that that'll drive wider consumer adoption versus an injectable. To date, a lot of the studies and the development work, there's been some challenges with that, some of it tied to the patient experience causing nausea. There's a tolerability trade-off. There's also been some challenges around the active ingredients and how they get absorbed into the system. Nevertheless, I do expect that's going to continue to be a focus area for customers. To date, and as we see it, auto injectors really remain, and direct injection really remain, the most reliable, effective, and widely adopted delivery format for these GLP-1 drugs. Oral formulations could certainly become a complement to that if you get into maintenance phases, as an example. Ryan McLeodInterim CEO at ATS Corporation00:39:24We continue to see that auto injectors will have a very prominent place in drug delivery for GLP-1 therapies. Michael GlenManaging Director at Raymond James00:39:34Okay. Can you remind us, I believe in the past you've indicated that GLP-1 was roughly 20% of the life science backlog? Are you able to give an update on where that figure sits today? Ryan McLeodInterim CEO at ATS Corporation00:39:49Yeah, it's still in that range. Michael GlenManaging Director at Raymond James00:39:52Okay. And then last one for me. Just looking at the SG&A. For the overall business, and I believe you gave the CAD 134.6 million figure as the run rate ex-share-based comps, is this the right level for—at this point in time, should we start to see leverage on SG&A? Should SG&A on that adjusted basis grow slower than overall revenue growth? Anne CybulskiInterim CFO at ATS Corporation00:40:23That's the goal. As part of our margin expansion focus internally, we do have a focus on SG&A. As the top line grows, I would expect to see that improved leverage drop through. Michael GlenManaging Director at Raymond James00:40:42Okay. Thank you. Operator00:40:46That concludes our question and answer session. I will now turn the call back over to Ryan McLeod for some final closing remarks. Ryan McLeodInterim CEO at ATS Corporation00:40:54Great. Thank you, operator. Thank you, everyone, for joining us today. We look forward to speaking to you on our third quarter call in February. Operator00:41:02This concludes today's conference call. Thank you for your participation. You may now disconnect.Read moreParticipantsExecutivesDavid OcampoHead of IRAnne CybulskiInterim CFORyan McLeodInterim CEOAnalystsJonathan GoldmanEquity Research Analyst at ScotiabankCherilyn RadbourneManaging Director of Equity Research at TD CowenMaxim SytchevManaging Director of Research in Industrial Products at National Bank of CanadaPatrick BaumannAnalyst at JPMorganSabahat KhanManaging Director of Global Research at RBCJustin KeywoodManaging Director of Institutional Research at StifelMichael GlenManaging Director at Raymond JamesPowered by